Answer
Rifampicin is not recommended with Symkevi because this strong CYP3A inducer decreased ivacaftor exposure by 89% and is expected to significantly decrease tezacaftor exposure, potentially reducing the efficacy of Symkevi and ivacaftor.
Sources for this answer
- Symkevi 100 mg/150 mg tablets PLGB 22352/0003Vertex Pharmaceuticals (Europe) Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 14Document updated
Sources checked